Uterine fibroids (UFs), also known as leiomyomas, are benign pelvic tumors that occur in nearly 70% of all reproductiveaged women (1, 2) . Some of these women will develop severe symptoms associated with the presence of these tumors. Annually, UFs account for over 200,000 hysterectomies in the U.S. This is due to the lack of long-term effective medical therapies (3) . Tumor growth is characterized by slow proliferation with increased deposition of extracellular matrix (proteoglycans and collagens), which participates in the fibrotic phenotype of UFs (3) . This process is usually in a steroidhormone dependent manner (2) . Besides steroid hormones, growth and maintenance of UFs are strongly related to growth factors, stem cells, and genetic and epigenetic abnormalities and other risk factors (1, 2) .
The myometrial smooth muscles are supplied by nerves (sympathetic, parasympathetic, sensory), which run in neurovascular bundles between myometrial cells (2) . Distortion of the nerves by masses of UFs leads to pelvic pain and dysmenorrhea symptoms (2) . Axonal degeneration could be pathological or physiological. The latter occurs in adults as a part of autonomic (sympathetic, parasympathetic) axon remodeling in the reproductive tract. Previous innervation remodeling animal studies in female reproductive tract provided insight into mechanisms underlying neuroplasticity associated with hormonal changes driven by changes in reproductive status. Sympathetic nerves are found to be the most susceptible uterine nerves to the cyclical variations in ovarian sex hormones; estrogen-induced uterine sympathetic axon degeneration (axon pruning), which regenerate rapidly during the low estrogen stages. The process is similar to what occurs during pregnancy, where uterine sympathetic innervation undergoes widespread degeneration, followed by reinnervation after delivery. Explanation of these findings is that estrogen acts directly on the myometrium to render it inhospitable to sympathetic axons, thus preventing the normally robust outgrowth induced by this target (2, 4) . Brain-derived neurotrophic factor is a neurotrophin that elicits uterine sympathetic denervation. However, neutralization of this growth factor failed to fully reverse estrogen's effects. This led investigators to explore novel target-derived, estrogen-regulated factors that could/may play a role in regulating such steroid-dependent innervations in human. Neurotrimin (NTM), a glycophatidylinositol) that is an anchored neuronal cell adhesion molecule belonging to the Ig-like cell adhesion molecule protein family. NTM presents in the uterus and is regulated by estrogen. NTM is known to regulate development/outgrowth of neuronal projections (neurites). In human, NTM gene is situated on chromosome 11q25 and encodes a 39-kDa protein. Interestingly, a mouse model revealed NTM to have opposing effects on different types of nerves; sensory and sympathetic neurons. NTM promotes neurite outgrowth of sensory neurons but inhibits neurite outgrowth in sympathetic neurons (2, 4) . However, the link between NTM and UF phenotype has not yet been explored.
Surgical intervention with hysterectomy is the main cure for UFs that results in tremendous health expenses, In the U.S., the yearly cost of UFs related management expenses is up to US$34.4 billion (1). Despite the recent shift of focus in the etiology of UFs from hormones to genetic aberrations and UF stem cells, to date, treatment with hormonal medications remains the mainstay therapy for UFs (2) . Currently, several medications are available for UFs but have varying degrees of success to help reduce the bulk symptoms of UFs (3) . Success in the medical management of steroiddependent disease processes such as symptomatic UFs is often due to the use of hormone modulators (2) . Ulipristal acetate (UPA) is a recent hormonal medication that could be considered as the first long-term treatment for UFs. UPA is a selective progesterone (P) receptor modulator. UPA can have both antagonist and partial agonist activity, depending on the levels of serum P (3). The promising action of UPA on suppression of UF phenotype was demonstrated by experimental as well as clinical studies. Several mechanisms underlying the potential decrease in size of UFs have been determined with the use of UPA. UPA affects the water content of the UFs, concomitantly with alterations in apoptosis and proliferation of UF cells. In addition, UPA has been shown to affect several markers related to fibrosis, inflammation, and angiogenesis of UFs (3, 5) . UPA treatment exhibits an inhibitory effect on UFs phenotype, concomitantly with an improvement of qualityof-life (3) . Although the success of clinical findings of UPA that conducted in both Europe and the United States, detailed mechanism underlying the UPA treatment and related clinical information is largely unknown.
In this issue of Fertility and Sterility, Parikh et al. (2) have demonstrated a novel finding that NTM, a neural cell adhesion molecule, is linking to UF phenotype. First, they showed differential expression of NTM in human UFs and myometrial tissue specimens by applying different methods. RNAsequencing analysis revealed increased expression of NTM transcripts in placebo patient UFs tissue relative to placebo patient myometrium, which confirmed by qRT-PCR. Additionally, the authors supplemented this confirmation by measuring NTM protein, which revealed a statistically significant increase in NTM protein levels in UFs as compared to matched myometrium of the placebo group patients. Furthermore, immunohistochemistry analysis demonstrated a qualitatively increase in cytoplasmic NTM staining in UFs as compared to myometrium in the placebo patients (2) . These studies suggest that abnormal increase in NTM expression correlates to UF phenotype.
Since steroid hormone contributes to the UF phenotype, Parikh et al. (2) determined the impact of steroid hormone (17 b-estradiol, medroxyprogresterone acetate) and hormone antagonists (fulvestrant and UPA) on NTM expression in both tissues and cell lines. Parikh et al.'s (2) in vitro studies demonstrated that treatment of UF cell lines with 17 b-estradiol resulted in an increase in NTM protein expression; however, treatment with fulvestrant (an Anti-estrogen medication) showed no significant change. Notably, upregulation of NTM protein in UFs cell lines following medroxyprogesterone acetate treatment was observed. Importantly, their clinical studies demonstrated that NTM gene expression of patient UFs was downregulated following UPA treatment, which confirmed by qRT-PCR, western blot analysis and immunohistochemistry analysis (2) . These basic and clinical research findings suggest that UPA treatment might be capable of reversing the abnormal neural innervation of uterine tissue induced by excess steroid hormone. The investigation suggested that the progression of the tumor state may be secondary to a disruption of NTM protein, which is involved in neuronal cell signaling leading to abnormal cellular regulation (2) . Previously, Krizsan-Aqbas et al. (4) showed that downregulation in NTM synthesis impaired estrogen's ability to reduce sympathetic innervation. Collectively, this study by Parikh et al. (2) further characterized the important role of steroid hormones linking to NTM expression in the pathetiology of UFs, which is consistent with previous finding that NTM is involved in mediating estrogen-induced sympathetic pruning (4) .
Although linking of UF phenotype to NTM is identified in this study, further characterization of the clinical relevance of NTM related to ethnic disparity in UFs is needed, because African-American women have a higher incidence rate and show increased risk of UFs than white women (5) . Accordingly, tissues used in this research study were collected from a clinical trial with both African-American and white women participants. In addition, further study is required in larger populations to define the NTM as a biomarker.
U.S. clinical trials of UPA for UFs showed that African-American women had a lower rate of amenorrhea responders and insignificant UFs size reduction. Considering the vitamin D deficiency as a risk factor for UFs and linking to health disparity, an additional study that could be considered is to investigate the effect of the combination treatment of UPA with vitamin D on NTM expression levels in myometrial cells from AA women. A recent study (5) showed that 1, 25 dihydroxyvitamin D3 enhanced the anti-UF effects of UPA in human UFs. Compared to UPA treatment alone, the combination treatment exhibits a more potent anti-UF phenotype effect (5) .
A previous study showed that the levels of NTM in the plasma of patients with heart failure correlated to outcome and treatment response (2) . To date, despite the use of several medications for UFs, serum biomarkers for assessing the response to medications are not available in clinical practices. In this regard, NTM might potentially provide a novel biomarker that may have an accurate prediction of treatment responses that would help to guide medical therapies in UFs, especially, with the recent data showing that UPA may provide a promising option for long-term relief from UFs.
Lastly, UFs are monoclonal tumors arising from the myometrium, often as multiple distinct tumors. Increasing evidence supports the hypothesis that these benign tumors originate from a stem cell population resident in the uterus. Notably, myometrial stem cells and UF stem cells have now been identified (1) . In this regard, it will be interesting to compare the expression patterns of NTM and other neural cell adhesion molecules between and UF stem cells and myometrial stem cells and investigate how they response to treatments of anti-UF drugs.
